• In August 2026, LivaNova PLC reported second-quarter 2026 sales of US$390.59 million and net income of US$108.57 million, with basic earnings per share from continuing operations rising to US$1.98.
• For the first half of 2026, the company’s turnaround was underscored by US$752.85 million in sales and a shift from a very large prior-year loss to net income of US$130.86 million.
• With this sharp improvement in profitability, we’ll now explore how LivaNova’s stronger earnings profile may reshape its existing investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

LivaNova Investment Narrative Recap

To own LivaNova, you need to believe in its ability to turn improving profitability into durable earnings, supported by neuromodulation and cardiopulmonary demand. The sharp swing to US$108.57 million in Q2 net income strengthens the near term earnings catalyst, but it does not remove key risks around pricing pressure, reimbursement limits and high R&D spending that could still weigh on margins if growth in procedures and adoption softens.

In that context, the recent PMA approval of the aura6000 system for adult obstructive sleep apnea feels particularly relevant. The earnings rebound arrives just as LivaNova is trying to build a new neuromodulation revenue stream in OSA, which could gradually diversify away from legacy VNS exposure. At the same time, the heavy investment and regulatory complexity behind aura6000 highlight how execution or reimbursement setbacks in this pipeline could quickly affect the improved earnings picture.

Yet against this stronger quarter, investors should be aware of how much pressure reimbursement decisions can still put on...

LivaNova's narrative projects $1.8 billion revenue and $220.8 million earnings by 2029.

Uncover how LivaNova's forecasts yield a $84.80 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming around US$1.6 billion of revenue and roughly US$178 million of earnings by 2029, and focus more on supply chain and reimbursement constraints than the recent results, so if you see this quarter differently it is worth comparing your view with these more pessimistic scenarios.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $84.80!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your LivaNova research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.